COVID-19 mRNA vaccination during pregnancy does not harm syncytiotrophoblast development

•Maternal response to COVID-19 messenger RNA vaccine does not impair trophoblast development.•SARS-CoV-2 antibodies in maternal blood do not impair trophoblast development.•This study supports the safety of COVID-19 messenger RNA vaccination during pregnancy. The safety of COVID-19 messenger RNA (mR...

Full description

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases Vol. 140; pp. 95 - 98
Main Authors: van Voorden, Jantine, de Groot, Christianne J.M., Ris-Stalpers, Carrie, Afink, Gijs B., van Leeuwen, Elisabeth
Format: Journal Article
Language:English
Published: Canada Elsevier Ltd 01-03-2024
Elsevier
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Maternal response to COVID-19 messenger RNA vaccine does not impair trophoblast development.•SARS-CoV-2 antibodies in maternal blood do not impair trophoblast development.•This study supports the safety of COVID-19 messenger RNA vaccination during pregnancy. The safety of COVID-19 messenger RNA (mRNA) vaccination during pregnancy remains a topic of concern. Its effect on placenta development has been poorly studied, even though this is essential for healthy pregnancy outcomes. We investigated the effect of the maternal immune response to COVID-19 mRNA vaccination on the development of syncytiotrophoblast (STB), a functional cell layer of the placenta where the maternal-fetal exchange takes place. We collected sera from pregnant women before vaccination and after the second vaccination with the Pfizer-BioNTech mRNA vaccine (n=12 paired samples). Human trophoblast stem cells were subjected to in vitro STB differentiation in the presence of the serum samples. Cell morphology, proliferation, and marker gene expression were assessed to determine STB differentiation. All cells obtained an STB-like morphology, upregulated STB markers, and downregulated trophoblast stem cell markers. We did not find any significant differences in the extent of differentiation between STBs treated with pre- and post-vaccination serum samples. This in vitro study suggests that the maternal inflammatory response and the presence of SARS-CoV-2 antibodies in the maternal blood are not harmful to STB development of the placenta. These findings support the growing body of evidence that COVID-19 mRNA vaccination during pregnancy is safe.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2024.01.014